Cargando…
A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin Sustains Antitubercular Efficacy in a Murine Infection Model
[Image: see text] Tuberculosis is the leading cause of death from a single infectious agent, ranking above the human immunodeficiency virus (HIV). Effective treatment using antibiotics is achievable, but poor patient compliance constitutes a major challenge impeding successful pharmacotherapeutic ou...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887855/ https://www.ncbi.nlm.nih.gov/pubmed/33615179 http://dx.doi.org/10.1021/acsptsci.0c00185 |
_version_ | 1783652055594827776 |
---|---|
author | Adeleke, Oluwatoyin A. Fisher, Logan Moore, Ian N. Nardone, Glenn A. Sher, Alan |
author_facet | Adeleke, Oluwatoyin A. Fisher, Logan Moore, Ian N. Nardone, Glenn A. Sher, Alan |
author_sort | Adeleke, Oluwatoyin A. |
collection | PubMed |
description | [Image: see text] Tuberculosis is the leading cause of death from a single infectious agent, ranking above the human immunodeficiency virus (HIV). Effective treatment using antibiotics is achievable, but poor patient compliance constitutes a major challenge impeding successful pharmacotherapeutic outcomes. This is often due to the prolonged treatment periods required and contributes significantly to the rising incidence of drug resistance, which is a major cause of tuberculosis mortality. Thus, innovative interventions capable of encouraging compliance and decreasing lengthy and frequent dosing are needed. Previously, aqueous tin protoporphyrin IX (SnPPIX), a heme oxygenase-1 inhibitor, administered as multiple daily intraperitoneal (IP) injections, showed considerable antitubercular efficacy and treatment shortening capabilities as a host-directed therapy in infected mice. Since daily IP injection is a clinically impractical administration approach, this proof-of-concept study aims to develop a novel, sustained action injectable formulation of SnPPIX for safe intramuscular (IM) administration. Herein, a SnPPIX-loaded poloxamer-poly(acrylic acid)-based thermoresponsive injectable formulation (SnPPIX-TIF) is designed for effective IM delivery. Results show SnPPIX-TIF is microparticulate, syringeable, injectable, and exhibits complete in vitro/in vivo gelation. Administered once weekly, SnPPIX-TIF significantly prolonged absorption and antimicrobial efficacy in infected mice. In addition, SnPPIX-TIF is well-tolerated in vivo; results from treated animals show no significant histopathologic alterations and were indistinguishable from the untreated control group, thus supporting its biocompatibility and preclinical safety. Overall, the IM delivery of the thermoresponsive injectable formulation safely sustains antitubercular effect in an infected murine model and decreases the number of injections required, signifying a potentially practical approach for future clinical translation. |
format | Online Article Text |
id | pubmed-7887855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-78878552021-06-22 A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin Sustains Antitubercular Efficacy in a Murine Infection Model Adeleke, Oluwatoyin A. Fisher, Logan Moore, Ian N. Nardone, Glenn A. Sher, Alan ACS Pharmacol Transl Sci [Image: see text] Tuberculosis is the leading cause of death from a single infectious agent, ranking above the human immunodeficiency virus (HIV). Effective treatment using antibiotics is achievable, but poor patient compliance constitutes a major challenge impeding successful pharmacotherapeutic outcomes. This is often due to the prolonged treatment periods required and contributes significantly to the rising incidence of drug resistance, which is a major cause of tuberculosis mortality. Thus, innovative interventions capable of encouraging compliance and decreasing lengthy and frequent dosing are needed. Previously, aqueous tin protoporphyrin IX (SnPPIX), a heme oxygenase-1 inhibitor, administered as multiple daily intraperitoneal (IP) injections, showed considerable antitubercular efficacy and treatment shortening capabilities as a host-directed therapy in infected mice. Since daily IP injection is a clinically impractical administration approach, this proof-of-concept study aims to develop a novel, sustained action injectable formulation of SnPPIX for safe intramuscular (IM) administration. Herein, a SnPPIX-loaded poloxamer-poly(acrylic acid)-based thermoresponsive injectable formulation (SnPPIX-TIF) is designed for effective IM delivery. Results show SnPPIX-TIF is microparticulate, syringeable, injectable, and exhibits complete in vitro/in vivo gelation. Administered once weekly, SnPPIX-TIF significantly prolonged absorption and antimicrobial efficacy in infected mice. In addition, SnPPIX-TIF is well-tolerated in vivo; results from treated animals show no significant histopathologic alterations and were indistinguishable from the untreated control group, thus supporting its biocompatibility and preclinical safety. Overall, the IM delivery of the thermoresponsive injectable formulation safely sustains antitubercular effect in an infected murine model and decreases the number of injections required, signifying a potentially practical approach for future clinical translation. American Chemical Society 2020-12-18 /pmc/articles/PMC7887855/ /pubmed/33615179 http://dx.doi.org/10.1021/acsptsci.0c00185 Text en This article not subject to U.S. Copyright. Published 2020 by American Chemical Society This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License (http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html) , which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes. |
spellingShingle | Adeleke, Oluwatoyin A. Fisher, Logan Moore, Ian N. Nardone, Glenn A. Sher, Alan A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin Sustains Antitubercular Efficacy in a Murine Infection Model |
title | A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin
Sustains Antitubercular Efficacy in a Murine Infection Model |
title_full | A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin
Sustains Antitubercular Efficacy in a Murine Infection Model |
title_fullStr | A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin
Sustains Antitubercular Efficacy in a Murine Infection Model |
title_full_unstemmed | A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin
Sustains Antitubercular Efficacy in a Murine Infection Model |
title_short | A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin
Sustains Antitubercular Efficacy in a Murine Infection Model |
title_sort | long-acting thermoresponsive injectable formulation of tin protoporphyrin
sustains antitubercular efficacy in a murine infection model |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887855/ https://www.ncbi.nlm.nih.gov/pubmed/33615179 http://dx.doi.org/10.1021/acsptsci.0c00185 |
work_keys_str_mv | AT adelekeoluwatoyina alongactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel AT fisherlogan alongactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel AT mooreiann alongactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel AT nardoneglenna alongactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel AT sheralan alongactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel AT adelekeoluwatoyina longactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel AT fisherlogan longactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel AT mooreiann longactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel AT nardoneglenna longactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel AT sheralan longactingthermoresponsiveinjectableformulationoftinprotoporphyrinsustainsantitubercularefficacyinamurineinfectionmodel |